partnership TO UNLOCK ACCESS To product for APAC TRIALS

Akesa, a pioneering Australia-based clinical trial supply company, has announced a strategic partnership with Rock8 Science to strengthen pharmaceutical supply chains in the Asia-Pacific.

The collaboration addresses the increasing demand for commercial medicines in clinical trial settings, ensuring studies across APAC have reliable access to essential pharmaceutical products.

Akesa Co-CEO Con Konstantopoulos said the partnership would support pharmaceutical manufacturers in managing increasing clinical trial demand while enabling a more transparent, efficient, and sustainable supply chain.

“”At present, many manufacturers don’t have visibility over how their products are being used in clinical trials, making it difficult to accurately predict demand and prevent supply disruptions,” Konstantopoulos said.

The partnership enables pharmaceutical manufacturers to better anticipate trial-related demand fluctuations through real-time insights, helping reduce the risk of supply disruptions and commercial stock shortages.

“Expanding our reach in APAC is vital to supporting sponsors, CDMOs and CROs with compliant, scalable access to trial medicines,” Konstantopoulos added. “This collaboration helps bridge a longstanding gap—connecting clinical demand with commercial supply strategies to ensure continuity and avoid delays.”

With more than half the world’s population, the APAC region continues to attract pharmaceutical investment due to its diverse patient base, cost efficiencies, and accelerated recruitment timelines.

Susan Heeley, Managing Director of Rock8 Science, said: “As more pharmaceutical companies prioritise APAC for clinical research, efficient medicine access remains a bottleneck. This partnership ensures products are available when and where they’re needed—ultimately supporting research that drives better global health outcomes.”

About